Physician

Ronald Yglesias, M.D.

According to 2025 Medicare claims, Ronald Yglesias, M.D. (NPI: 1619388840) practices rheumatology in the Miami-Miami Beach-Kendall, FL market, with the plurality of this provider's patient population coming from Miami-Dade, FL. This provider's primary affiliated billing organization is NORMAN B. GAYLIS M.D. PA (NPI: 1003055203; TIN: 650901240) and primary practice location at 33180-1264. Yglesias is affiliated with the American Choice Healthcare, LLC (ACO ID: D0086), participating under the REACH model.

Yglesias' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 359 traditional Medicare patients, billed 100,988 HCPCS/CPT codes, and received $1,096,504 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 3,267 prescription claims across 552 beneficiaries totaling $5,480,028 in drug costs, led by Rinvoq (Upadacitinib). DME data shows 12 claims. Open Payments data shows 38 records totaling $841. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $52,388 to $1,096,504. Similarly, Part D prescription costs have risen steadily, from $35,386 to $5,480,028. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	74	2,724	$52,388
2018	252	26,050	$572,291
2019	268	19,091	$471,868
2020	244	44,064	$679,525
2021	279	95,566	$1,046,254
2022	325	103,058	$1,008,426
2023	336	112,571	$1,202,703
2024	359	100,988	$1,096,504

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	42	192	$35,386
2016	67	559	$107,251
2017	150	572	$226,953
2018	433	2,278	$1,952,739
2019	453	3,492	$3,979,382
2020	462	3,590	$4,159,253
2021	476	3,252	$4,711,286
2022	526	3,316	$4,845,267
2023	569	3,519	$4,957,767
2024	552	3,267	$5,480,028

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	12	$46,170

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	84	84	$130
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	251	501	$99
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	104	413	$56
77080	Dxa bone density measurement of hip, pelvis, spine	110	111	$40
J0897	Injection, denosumab, 1 mg	137	12,300	$21

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rinvoq	Upadacitinib	162	5,160	$1,101,361
Humira(Cf) Pen	Adalimumab	44	1,244	$472,359
Prolia	Denosumab	213	38,250	$366,203
Xeljanz Xr	Tofacitinib Citrate	58	1,860	$355,437
Enbrel Sureclick	Etanercept	41	1,148	$326,933

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	12	$46,170

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	38	$841	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ronald Yglesias, M.D.?

Tedicare shows public-source Medicare data for Ronald Yglesias, M.D. (NPI 1619388840), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ronald Yglesias, M.D. have ACO affiliation data?

Ronald Yglesias, M.D. is shown with ACO affiliation data for American Choice Healthcare, LLC (REACH, ACO ID D0086).

What billing organization is linked to Ronald Yglesias, M.D.?

Ronald Yglesias, M.D. is linked to NORMAN B. GAYLIS M.D. PA (billing NPI 1003055203) in the available physician profile data.

Does Ronald Yglesias, M.D. have Open Payments data?

Ronald Yglesias, M.D. has 38 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.